Arama Sonuçları - C. Lebbe

Corrigendum to: Efficacy of neoadjuvant pembrolizumab in a primary cutaneous stage II non-operated melanoma Yazar: M. Amiot, M. Battistella, M. Bezier, C. Lebbé, B. Baroudjian

Tam Metin Erişim

Efficacy of neoadjuvant pembrolizumab in a primary cutaneous stage II non-operated melanoma Yazar: M. Amiot, M. Battistella, Maud Bezier, C. Lebbé, B. Baroudjian

Tam Metin Erişim

Discoidin domain receptor 1, a melanoma immunomodulator Yazar: C. Lutz, A. Lourenço, C. Reger de Moura, B. Louveau, A. Marie-Cardine, C. Lebbé, S. Mourah

Tam Metin Erişim

Kindlin-3 inactivation mediates melanoma agressiveness through crosstalk with the collagen-activated tyrosine kinase receptor DDR1 Yazar: C. Reger de Moura, B. Louveau, F. Jouenne, P. Vilquin, M. Battistella, Y. Bellahsen, A. Sadoux, S. Menashi, M. Mancini, N. Dumaz, C. Lebbé, S. Mourah

Tam Metin Erişim

Whole transcriptome sequencing: Optimizing molecular classification and management of rare skin cancers Yazar: B. Louveau, F. Jouenne, A. Sadoux, M. Mancini, C. Reger de Moura, B. Baroudjian, L. Da Meda, J. Brayet, P. Vilquin, C. Lebbé, M. Battistella, S. Mourah

Tam Metin Erişim

Updated outcomes of AdjuMel study: real-world data in patients with resected stage III-IV melanoma treated with adjuvant nivolumab in France Yazar: S. Dalle, P. Saiag, C. Lebbé, J.-J. Grob, B. Dréno, S. Dalac, B. Asselain, F. Skowron, S. Darras, N. Jovenin, G. Quereux, A. Khammari, C. Rieuf, F. Brellier, S. Houssou, L. Mortier

Tam Metin Erişim

HPV vaccination practices among organ transplant recipients in France Yazar: J. de Quatrebarbes, J. Chanal, E. Ducroux, M.-T. Leccia, J. Kanitakis, S. Guegan, A. Dadban, B. Sassolas, J. Deylon, N. Malissen, F. Boukari, A. Du Thanh, L. Boussemart, C. Lebbé, S. Barete

Tam Metin Erişim

Skin adnexal carcinomas DNA genomic profiling uncovers oncogenic pathways and potential therapeutic targets Yazar: B. Louveau, I. Nakouri, F. Jouenne, B. Baroudjian, A. Sadoux, L. Da Meda, A. Osio, F. Reinhart, J. Robert, M. Mancini, F. Herms, B. Cribier, L. Mortier, T. Jouary, N. Basset-Seguin, C. Lebbé, S. Mourah, M. Battistella

Tam Metin Erişim

Early recurrence in a pooled international cohort of melanoma patients treated with adjuvant nivolumab in a real-world setting Yazar: L. Mortier, R. Gutzmer, V. Atkinson, S. Dalle, P. Saiag, B. Neyns, A. Rorive, P. Parente, M. Weichenthal, J.-J. Grob, C. Lebbé, P. Mohr, T. Eigentler, L. McDonald, L. Willemot, F. Brellier, O. Bakharevski, S. Houssou, M. Jadhao, D. Schadendorf

Tam Metin Erişim

A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastati... Yazar: G.V. Long, R. Gutzmer, A. Haydon, E. Muñoz Couselo, C. Lebbé, M. Carlino, W. Chow, F. Couture, P. Lau, F. Spagnolo, A.J. Alves Wainstein, D. Palmieri, C. Rojas García, G. de Velasco Oria de Rueda, I. Mehmi, D. Patel, A. Shaikh, N.R. Chowdhury, S. Bathena, S. Suryawanshi, P. Rutkowski

Tam Metin Erişim

Biomarker and updated clinical data for RP1 plus nivolumab in anti–PD-1–failed melanoma from the IGNYTE trial demonstrate reversal of mechanisms of resistance to immune checkpoint... Yazar: C. Robert, P.K. Bommareddy, T.M. Wise-Draper, J.J. Sacco, G.K. In, E. Muñoz Couselo, D. Schadendorf, J. Niu, G.M. Beasley, B. Chmielowski, M.M. Milhem, T.L. Bowles, K.K. Tsai, C. Lebbé, C. Gaudy-Marqueste, A. Samson, J. Zhu, M. Viana, C. Tucci, B. Paratala, J.W. Hou, M.K. Wong

Tam Metin Erişim

Translating ctDNA into melanoma care: an international expert survey Yazar: G. Geidel, N. Fekade, K. Raabe, D.J. Smit, L. Adam, I. Heidrich, A. Rünger, J. Kött, T. Zell, T. Amaral, P.A. Ascierto, P. Corrie, R. Dummer, A. Eggermont, J. Guo, J.C. Hassel, M. Jalving, D.B. Johnson, L. Kandolf, J.M. Kirkwood, C. Lebbé, R. Lee, G.V. Long, P. Lorigan, J. Malvehy, J. Mangana, P. Mohr, S.P. Patel, H. Rizos, C. Robert, D. Schadendorf, V.K. Sondak, I.M. Svane, A. Wainstein, J.S. Zager, K. Pantel, A. Hauschild, C. Gebhardt

Tam Metin Erişim

SUPRAME: A Phase 3 trial evaluating anzutresgene autoleucel (anzu-cel, IMA203) PRAME-directed T-cell receptor T-cell therapy vs investigator’s choice in previously treated advanced... Yazar: A. Betof, M. Jalving, J. Haanen, A. van der Veldt, F. Schmitz, A. Busse, D. Schadendorf, J. Hassel, E. Wagner, C. Gebhardt, B. Schilling, C. Berking, S. Patel, D. Davar, L. Hernandez-Aya, A.J. Olszanski, J. Smithy, L. Karapetyan, Y. Xing, S. Hu-Lieskovan, J. Isaacs, M. Hurwitz, R. Wu, A. Poklepovic, M. Taylor, T. Mitchell, B. Chmielowski, S. Lee, M. McKean, C. Cowey, S. Moschos, A. Haugh, J. Moser, B. Sharma, J.M. Mammen, M. Dimitrova, R. Amaria, R. Seedor, P. Hausner, S. Chandrasekaran, E. Whitman, D. Olson, V. Ma, A.Z. Dudek, L. Fecher, A. Daud, D. McDermott, H. Viray, B. Solomon, G. Daniels, R. Chen, M. Seetharam, D. Sahasrabudhe, S. Nair, A.R. Naqash, J. Terhune, C. Robert, C. Lebbe, L. Mortier, J.C. Simon, C. Franklin, M.O. Butler, A. Weppler, M. Anaka, R. Jamal, D. Josephs, Y. Wu, P. Corrie, P. Spiliopoulou, J. Lim, I. Karydis, M. Payne, A. Furness, H. Shaw, D. Krishna, C. Britten, M. Wermke

Tam Metin Erişim